Ewelina Musielak

Dr. Ewelina Musielak


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2022 in Materials
Verified
Journal Article
Open access
PDF file
EMEwelina Musielak
Ewelina Musielak
Agnieszka Feliczak-GuzikAgnieszka Feliczak-Guzik
Agnieszka Feliczak-Guzik
INIzabela Nowak
Izabela Nowak
Currently, carriers of active ingredients in the form of particles of a size measured in nanometers are the focus of interest of research centers worldwide. So far, submicrometer emulsions, liposomes, as well as microspheres, and nanospheres made of biodegradable polymers have been used in medicine. Recent studies show particular interest in nanoparticles based on lipids, and at the present time, are even referred to as the “era of lipid carriers”. With the passage of time, lipid nanoparticles of the so-called first and second generation, SLN (Solid Lipid Nanoparticles) and nanostructured lipid carriers and NLC (Nanostructured Lipid Carriers), respectively, turned out to be an alternative for all imperfections of earlier carriers. These carriers are characterized by a number of beneficial functional properties, including, among others, structure based on lipids well tolerated by the human body, high stability, and ability to carry hydro- and lipophilic compounds. Additionally, these carriers can enhance the distribution of the drug in the target organ and alter the pharmacokinetic properties of the drug carriers to enhance the medical effect and minimize adverse side effects. This work is focused on the current review of the state-of-the-art related to the synthesis and applications of popular nanoparticles in medicine, with a focus on their use, e.g., in COVID-19 vaccines.

28 March 2022 in Molecules
Verified
Journal Article
Open access
PDF file
EMEwelina Musielak
Ewelina Musielak
Agnieszka Feliczak-GuzikAgnieszka Feliczak-Guzik
Agnieszka Feliczak-Guzik
INIzabela Nowak
Izabela Nowak
Solid lipid nanoparticles (SLNs) have been synthesized as potential drug delivery systems. They are classified as solid lipid nanocarriers that can successfully carry both hydrophilic and hydrophobic drugs. SLNs are based on a biocompatible lipid matrix that is enzymatically degraded into natural components found in the human body. Solid lipid nanoparticles are suitable for the incorporation of hydrophobic active ingredients such as curcumin. The study included the optimization of lipid nanoparticle composition, incorporation of the active compound (curcumin), a stability evaluation of the obtained nanocarriers and characterization of their lipid matrix. Through process optimization, a dispersion of solid lipid nanoparticles (solid lipid:surfactant—2:1.25 weight ratio) predisposed to the incorporation of curcumin was developed. The encapsulation efficiency of the active ingredient was determined to be 99.80%. In stability studies, it was found that the most suitable conditions for conducting high-pressure homogenization are 300 bar pressure, three cycles and a closed-loop system. This yields the required values of the physicochemical parameters (a particle size within a 200–450 nm range; a polydispersity index of <30%; and a zeta potential of about |±30 mV|). In this work, closed-loop high-pressure homogenization was used for the first time and compared to the currently preferred open-loop method.

5 November 2024 in Cosmetics
Verified
Journal Article
Open access
PDF file
EMEwelina Musielak
Ewelina Musielak
Violetta Krajka-KuźniakVioletta Krajka-Kuźniak
Violetta Krajka-Kuźniak
Skin diseases are a common health problem affecting millions of people worldwide. Effective treatment often depends on the precise delivery of drugs to the affected areas. One promising approach is currently the transdermal drug delivery system (TDDS), whose significant challenge is the poor penetration of many compounds into the skin due to the stratum corneum (SC), which acts as a formidable barrier. To overcome this limitation, nanocarriers have emerged as a highly effective alternative. This review discusses the use of liposomes and ethosomes for transdermal drug delivery. Liposomes are micro- or nanostructures consisting of a lipid bilayer surrounding an aqueous core. They facilitate transdermal drug penetration and may be advantageous for site-specific targeting. Some methods of treating skin diseases involve incorporating drugs such as acyclovir, dithranol, and tretinoin or bioactive compounds such as fluconazole, melanin, glycolic acid, kojic acid, and CoQ10 into nanocarriers. The inability of liposomes to pass through the narrowed intercellular channels of the stratum corneum led to the invention of lipid-based vesicular systems such as ethosomes. They are structurally similar to conventional liposomes, as they are prepared from phospholipids, but they contain a high ethanol concentration. Ethosomes are noninvasive carriers that allow drugs to reach the deep layers of the skin. Examples of commonly used substances and drugs combined with ethosomes in cosmetics include methotrexate, ascorbic acid, vitamin A and E, and colchicine. A significant development in this area is the use of rutin-loaded ethosomes. Encapsulating rutin in ethosomes significantly improves its stability and enhances skin penetration, allowing more efficient delivery to deeper skin layers. In cosmetics, rutin–ethosome formulations are used to protect the skin from oxidative stress, reduce redness, and improve capillary strength, making it a valuable formulation in anti-aging and anti-inflammatory products. The results of the first clinical trial of the acyclovir–ethosome formulation confirm that ethosomes require further investigation. The work provides an update on recent advances in pharmaceutical and cosmetic applications, mentioning the essential points of commercially available formulations, clinical trials, and patents in the recent past.

3 January 2025 in Micro
Verified
Journal Article
Open access
PDF file
EMEwelina Musielak
Ewelina Musielak
Violetta Krajka-KuźniakVioletta Krajka-Kuźniak
Violetta Krajka-Kuźniak
Due to their biocompatibility, nontoxicity, and surface conjugation properties, nanomaterials are effective nanocarriers capable of encapsulating chemotherapeutic drugs and facilitating targeted delivery across the blood–brain barrier (BBB). Although research on nanoparticles for brain cancer treatment is still in its early stages, these systems hold great potential to revolutionize drug delivery. Glioblastoma multiforme (GBM) is one of the most common and lethal brain tumors, and its heterogeneous and aggressive nature complicates current treatments, which primarily rely on surgery. One of the significant obstacles to effective treatment is the poor penetration of drugs across the BBB. Moreover, GBM is often referred to as a “cold” tumor, characterized by an immunosuppressive tumor microenvironment (TME) and minimal immune cell infiltration, which limits the effectiveness of immunotherapies. Therefore, developing novel, more effective treatments is critical to improving the survival rate of GBM patients. Current strategies for enhancing treatment outcomes focus on the controlled, targeted delivery of chemotherapeutic agents to GBM cells across the BBB using nanoparticles. These therapies must be designed to engage specialized transport systems, allowing for efficient BBB penetration, improved therapeutic efficacy, and reduced systemic toxicity and drug degradation. Lipid and inorganic nanoparticles can enhance brain delivery while minimizing side effects. These formulations may include epitopes—small antigen fragments that bind directly to free antibodies, B cell receptors, or T cell receptors—that interact with transport systems and enable BBB crossing, thereby boosting therapeutic efficacy. Lipid-based nanoparticles (LNPs), such as liposomes, niosomes, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs), are among the most promising delivery systems due to their unique properties, including their size, surface modification capabilities, and proven biosafety. Additionally, inorganic nanoparticles such as gold nanoparticles, mesoporous silica, superparamagnetic iron oxide nanoparticles, and dendrimers offer promising alternatives. Inorganic nanoparticles (INPs) can be easily engineered, and their surfaces can be modified with various elements or biological ligands to enhance BBB penetration, targeted delivery, and biocompatibility. Strategies such as surface engineering and functionalization have been employed to ensure biocompatibility and reduce cytotoxicity, making these nanoparticles safer for clinical applications. The use of INPs in GBM treatment has shown promise in improving the efficacy of traditional therapies like chemotherapy, radiotherapy, and gene therapy, as well as advancing newer treatment strategies, including immunotherapy, photothermal and photodynamic therapies, and magnetic hyperthermia. This article reviews the latest research on lipid and inorganic nanoparticles in treating GBM, focusing on active and passive targeting approaches.

12 September 2022 in Materials
Verified
Journal Article
Open access
PDF file
EMEwelina Musielak
Ewelina Musielak
Agnieszka Feliczak-GuzikAgnieszka Feliczak-Guzik
Agnieszka Feliczak-Guzik
MJMietek Jaroniec
Mietek Jaroniec
INIzabela Nowak
Izabela Nowak
This work shows that hierarchical zeolites are promising systems for the delivery of biologically relevant hydrophobic substances, such as curcumin. The validity of using piperine as a promoter of curcumin adsorption was also evaluated. The use of pure curcumin is not medically applicable due to its low bioavailability and poor water solubility. To improve the undesirable properties of curcumin, special carriers are used to overcome these shortcomings. Hierarchical zeolites possessing secondary mesoporosity are used as pharmaceutical carrier systems for encapsulating active substances with low water solubility. This porosity facilitates access of larger reagent molecules to the active sites of the material, preserving desirable adsorption properties, acidity, and crystallinity of zeolites. In this work, methods are proposed to synthesize hierarchical zeolites based on a commercial FAU-type zeolite. Studies on the application and adsorption kinetics of curcumin using commercial FAU-type zeolite and hierarchical zeolites based on commercial FAU-type zeolite are also included.

12 August 2025 in Cosmetics
Verified
Journal Article
Open access
PDF file
EMEwelina Musielak
Ewelina Musielak
Violetta Krajka-KuźniakVioletta Krajka-Kuźniak
Violetta Krajka-Kuźniak
Ultraviolet radiation (UVR) is a major contributor to skin aging and carcinogenesis, primarily through the induction of DNA damage. While conventional sunscreens provide passive protection by blocking UVR, active photoprotection using DNA repair enzymes offers a strategy to reverse UV-induced DNA lesions at the molecular level. Enzymes such as photolyase, T4 endonuclease V, and 8-oxoguanine glycosylase address distinct types of DNA damage through light-dependent and -independent mechanisms, complementing the skin’s endogenous repair systems. Advances in nanocarrier technologies and encapsulation methods have improved the stability and delivery of these enzymes in topical formulations. Emerging evidence from clinical studies indicates their potential in reducing actinic keratoses, pigmentation disorders, and photoaging signs, although challenges in regulatory approval, long-term efficacy validation, and formulation optimization remain. This review provides a comprehensive synthesis of the mechanistic, clinical, and formulation aspects of enzyme-based photoprotection, outlines regulatory and ethical considerations, and highlights future directions, including CRISPR-based repair and personalized photoprotection strategies, establishing enzyme-assisted sunscreens as a next-generation approach to comprehensive skin care.